亚临床甲状腺疾病的新挑战：从指南到实践  

New challenge in subclinical thyroid disease： from guideline to practice

作　　者：陈国芳[1] 刘超[1] 

机构地区：[1]南京中医药大学附属中西医结合医院,江苏省中医药研究院,内分泌代谢病院区,210028

出　　处：《中华内分泌代谢杂志》2017年第1期88-90,共3页Chinese Journal of Endocrinology and Metabolism

摘　　要：亚临床甲状腺疾病对健康的危害已经明确，针对亚临床甲状腺疾病的管理指南对临床工作具有重要指导作用。然而，正常范围内的甲状腺功能亦与房颤、冠心病、骨质疏松和脂质代谢异常等风险相关，且受年龄、其他疾病状态等因素的影响，故以促甲状腺素（TSH）异常作为是否干预亚临床甲状腺疾病的阈值存在局限性。对此，有学者提出，分级诊断甲状腺功能异常，以及根据个体TSH值和合并症建立危险分层来评估是否给予干预。Accumulating evidence showed the associations between subclinical hyperthyroidism or subclinical hypothyroidism and adverse health outcomes. The related guidelines could be very helpful in making treatment decisions. However, even within the reference range, thyroid function is associated with adverse health outcomes, such as atrial fibrillation, coronary artery disease, osteoporosis, and dyslipidemia. Also, there is limitation to use TSH value as intervention threshold by the influence of age and other diseases. In this regard, a grading system is proposed to diagnose thyroid dysfunction, and risk stratification according to individual TSH values and comorbidities would be constructed to evaluate the utility of treatment.

关 键 词：亚临床甲状腺功能亢进 亚临床甲状腺功能减退 促甲状腺素 

分 类 号：R581[医药卫生—内分泌]